5-methylurapidil has been researched along with Prostatic Hyperplasia in 2 studies
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kenny, B | 1 |
| Ballard, S | 1 |
| Blagg, J | 1 |
| Fox, D | 1 |
| Elworthy, TR | 1 |
| Ford, AP | 1 |
| Bantle, GW | 1 |
| Morgans, DJ | 1 |
| Ozer, RS | 1 |
| Palmer, WS | 1 |
| Repke, DB | 1 |
| Romero, M | 1 |
| Sandoval, L | 1 |
| Sjogren, EB | 1 |
| Talamás, FX | 1 |
| Vazquez, A | 1 |
| Wu, H | 1 |
| Arredondo, NF | 1 |
| Blue, DR | 1 |
| DeSousa, A | 1 |
| Gross, LM | 1 |
| Kava, MS | 1 |
| Lesnick, JD | 1 |
| Vimont, RL | 1 |
| Williams, TJ | 1 |
| Zhu, QM | 1 |
| Pfister, JR | 1 |
| Clarke, DE | 1 |
1 review available for 5-methylurapidil and Prostatic Hyperplasia
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlle | 1997 |
1 other study available for 5-methylurapidil and Prostatic Hyperplasia
| Article | Year |
|---|---|
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Amid | 1997 |